Other Information
−Removed: During the period from July 1, 2025 to September 30, 2025, our officers (as defined in Rule 16a-1(f) under the Exchange Act) and/or directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:
−Removed: Name and Title Action Date Trading Arrangement Total Shares Authorized
+Added: During the period from January 1, 2026 to March 31, 2026, our officers (as defined in Rule 16a-1(f) under the Exchange Act) and/or directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:
+Added: Name and Title Action*
+Added: Date Trading Arrangement Total Shares Authorized
to be Sold****
−Removed: Rule 10b5-1* Non-Rule 10b5-1**
−Removed: William Rastetter
+Added: Rule 10b5-1**
+Added: Non-Rule 10b5-1***
+Added: David Boyer Adoption
33,832 2/23/2027
−Removed: George Morrow
+Added: Chief Corporate Affairs Officer
+Added: Julie Cooke Adoption
3/2/2026 X 36,937 12/31/2026
−Removed: Eric Benevich
+Added: Chief Human Resources Officer
+Added: Ingrid Delaet Adoption
2/27/2026 X 51,818 2/28/2027
−Removed: Chief Commercial Officer
+Added: Chief Regulatory Officer
+Added: Kyle Gano Adoption
2/4/2026 X 60,000 2/6/2027
−Removed: Leslie Norwalk
+Added: Chief Executive Officer
+Added: Kevin Gorman Adoption
2/17/2026 X 245,088 2/6/2027
+Added: Jude Onyia Adoption
+Added: 2/25/2026 X 22,000 2/15/2027
+Added: Chief Scientific Officer
+Added: Richard Pops Adoption
+Added: 2/13/2026 X 30,000 8/15/2026
+Added: Stephen Sherwin Adoption
+Added: 3/5/2026 X 25,000 6/4/2027
+Added: Matthew Abernethy Termination 1/20/2026 X 3,618 2/28/2028
+Added: Chief Financial Officer Termination 1/20/2026 X 2,704 2/28/2027
+Added: Termination 1/20/2026 X 1,283 2/15/2026
+Added: Eric Benevich Termination 1/20/2026 X 3,168 2/28/2028
+Added: Chief Commercial Officer Termination 1/20/2026 X 2,196 2/28/2027
+Added: Termination 1/20/2026 X 1,207 2/15/2026
+Added: David Boyer Termination 1/20/2026 X 2,490 2/28/2028
+Added: Chief Corporate Affairs Officer Termination 1/20/2026 X 1,910 2/28/2027
+Added: Termination 1/20/2026 X 1,104 2/15/2026
+Added: Julie Cooke Termination 1/20/2026 X 2,265 2/28/2028
+Added: Chief Human Resources Officer Termination 1/20/2026 X 1,592 2/28/2027
+Added: Termination 1/20/2026 X 916 2/15/2026
+Added: Ingrid Delaet Termination 1/20/2026 X 2,265 2/28/2028
+Added: Chief Regulatory Officer Termination 1/20/2026 X 1,432 2/28/2027
+Added: Termination 1/20/2026 X 422 2/15/2026
+Added: Kyle Gano Termination 1/20/2026 X 3,618 2/28/2028
+Added: Chief Executive Officer Termination 1/20/2026 X 2,704 2/28/2027
+Added: Termination 1/20/2026 X 1,541 2/15/2026
+Added: Kevin Gorman Termination 1/20/2026 X 9,036 2/28/2028
+Added: Termination 1/20/2026 X 5,664 2/28/2027
+Added: Termination 1/20/2026 X 2,707 2/15/2026
+Added: Darin Lippoldt Termination 1/20/2026 X 3,258 2/28/2028
+Added: Chief Legal Officer Termination 1/20/2026 X 2,196 2/28/2027
+Added: Termination 1/20/2026 X 1,250 2/15/2026
+Added: Jude Onyia Termination 1/20/2026 X 4,341 2/28/2028
+Added: Chief Scientific Officer Termination 1/20/2026 X 2,864 2/28/2027
+Added: Termination 1/20/2026 X 2,457 2/15/2026
______________
+Added: * The Rule 10b5-1 trading arrangements reflected in the termination rows dated January 20, 2026 were sell-to-cover arrangements authorizing the pre-arranged sale of shares to satisfy employee tax withholding obligations arising exclusively from the vesting of restricted stock units (RSUs) and performance restricted stock units (PRSUs) and the related issuance of shares.
+Added: These arrangements were terminated in connection with the Company's transition to net share settlement of RSUs and PRSUs, pursuant to which the Company withholds from the shares otherwise issuable upon settlement a number of shares sufficient to satisfy applicable tax withholding obligations and issues the remaining net shares to the award recipient.
+Added: Shares withheld under net share settlement are not sold in market transactions.
** Intended to satisfy the affirmative defense of Rule 10b5-1(c)
2 unchanged sentences
The number of shares sold is dependent on the satisfaction of certain conditions as set forth in the written plan and the satisfaction of applicable vesting conditions of equity awards.
−Removed: In addition, our executive officers have entered into sell-to-cover arrangements adopted pursuant to Rule 10b5-1 authorizing the pre-arranged sale of shares to satisfy tax withholding obligations of the Company arising exclusively from the vesting of time-vesting or performance-vesting restricted stock units and the related issuance of shares.
−Removed: The amount of shares to be sold to satisfy the Company’s tax withholding obligations under these arrangements is dependent on future events which cannot be known at this time, including the future trading price of Company shares.
−Removed: The expiration date relating to these arrangements is dependent on future events which cannot be known at this time, including the final vest date of the applicable time-vesting or performance-vesting restricted stock units and the officer’s termination of service.
The following exhibits are filed as part of, or incorporated by reference into, this report:
36 unchanged sentences
NEUROCRINE BIOSCIENCES, INC.
−Removed: October 28, 2025
/s/ Matthew C.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.